Fluoroquinolone antibiotic litigation: the Cipro and Levaquin tendon, neuropathy, and aortic injury claims, the FDA's escalating boxed warnings, the largely resolved MDL, and the still-active aortic aneurysm cases

Fluoroquinolone antibiotics are among the most widely prescribed drugs in the United States, used for decades to treat respiratory infections, urinary tract infections, and a range of bacterial conditions. The brand names are familiar: Cipro (ciprofloxacin, manufactured by Bayer), Levaquin (levofloxacin, manufactured by Johnson & Johnson's Janssen Pharmaceuticals), and Avelox (moxifloxacin, manufactured by Merck). Other fluoroquinolones include Floxin (ofloxacin) and Factive (gemifloxacin).

The litigation involving these drugs has spanned more than a decade, driven by three categories of serious injury: tendon rupture, peripheral neuropathy, and aortic aneurysm and dissection. The FDA has issued increasingly severe warnings over that period, culminating in boxed warnings (its most serious alert category), use restrictions, and the coining of a new clinical term for the syndrome of co-occurring injuries.

The honest assessment in 2026: the main litigation waves for tendon and neuropathy injuries have largely concluded through confidential settlements. The aortic aneurysm claims are still active in some jurisdictions. And the FDA's recognition of "fluoroquinolone-associated disability" (FQAD) as a syndrome continues to raise awareness among patients who may not have connected their symptoms to the medication.

The drugs and the scope of prescribing

Fluoroquinolones are broad-spectrum antibacterial drugs that work by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication. They were valued for their broad coverage and oral bioavailability (they could be taken as pills rather than requiring IV administration).

The prescribing scope was enormous. Ciprofloxacin (Cipro) alone was prescribed tens of millions of times annually in the United States. The drugs were used for urinary tract infections, respiratory infections (sinusitis, bronchitis, pneumonia), skin infections, and bone and joint infections. Military and government stockpiles included ciprofloxacin for anthrax prophylaxis.

The breadth of prescribing is what gives the litigation its scale. Many of the patients who were injured were taking fluoroquinolones for uncomplicated infections (sinusitis, simple UTIs) that could have been treated with safer alternatives. The FDA ultimately concluded that the risks of fluoroquinolones outweigh the benefits for uncomplicated infections, restricting their use to situations where no alternative treatment exists.

The three injury categories

Tendinitis and tendon rupture (FDA Boxed Warning 2008). Fluoroquinolones weaken tendons, particularly the Achilles tendon, by disrupting collagen synthesis. The injury can range from tendinitis (inflammation and pain) to complete tendon rupture, which can require surgery and cause permanent disability. The risk is highest in patients over 60, patients taking corticosteroids, and organ transplant recipients.

The FDA added the Boxed Warning (its most serious warning category) to all fluoroquinolone labels in 2008, requiring prominent disclosure of the tendon rupture risk. The tendon injury litigation was the first major wave of fluoroquinolone lawsuits.

Peripheral neuropathy (FDA label change 2013). Fluoroquinolones can cause peripheral neuropathy, a condition involving damage to the peripheral nerves that can produce burning pain, tingling, numbness, weakness, and changes in sensation in the arms and legs. The nerve damage can begin within days of starting the medication and can be permanent.

In 2013, the FDA mandated label changes for all fluoroquinolones to highlight the risk of potentially irreversible peripheral neuropathy. The neuropathy litigation was the second major wave, with cases consolidated in MDL 2642 in the District of Minnesota before Judge John R. Tunheim.

Aortic aneurysm and dissection (FDA warning 2018). A 2015 study published in JAMA Internal Medicine found that fluoroquinolone use approximately doubled the risk of aortic aneurysm (a dangerous bulging of the aorta) and aortic dissection (a tear in the aortic wall). Aortic rupture can be fatal.

In 2018, the FDA issued a safety communication warning about the increased risk of aortic aneurysm and dissection and required label updates. The aortic injury litigation is the most recent wave and remains active in some jurisdictions.

The FDA's escalating warnings

The history of FDA warnings illustrates the gradual recognition of the scope of the problem:

2008: Boxed Warning added for tendinitis and tendon rupture risk.

2013: Label changes mandated for the risk of potentially irreversible peripheral neuropathy.

2016: FDA safety communication restricting use; fluoroquinolones should not be used for uncomplicated sinusitis, bronchitis, or urinary tract infections when alternative treatments are available. The FDA also recognized the syndrome of multiple co-occurring effects (tendons, muscles, joints, nerves, central nervous system) and recommended the term "fluoroquinolone-associated disability" (FQAD).

2018: Warning about the increased risk of aortic aneurysm and dissection.

2018: Strengthened warnings about mental health effects (anxiety, depression, hallucinations, suicidal ideation, confusion).

Additional recognized risks include severe hypoglycemia (blood sugar drops), phototoxicity (severe sunburn reactions), and central nervous system effects (seizures, tremors, psychotic reactions). The cumulative weight of these warnings made fluoroquinolones one of the most heavily-warned drug classes in the FDA's system.

The litigation history

The MDL (MDL 2642). The Judicial Panel on Multidistrict Litigation consolidated many of the Levaquin peripheral neuropathy cases into MDL 2642 in the U.S. District Court for the District of Minnesota, before Judge John R. Tunheim. The MDL addressed the failure-to-warn claims for peripheral neuropathy, with plaintiffs alleging that the manufacturers knew or should have known about the neuropathy risk and failed to warn adequately.

Most of the MDL cases were resolved through confidential settlements. The terms were not disclosed, but the volume of settlements (Johnson & Johnson faced more than 2,000 Levaquin lawsuits) indicates substantial aggregate payments. The MDL is still technically active but is in its winding-down phase, with the manufacturers urging termination.

Tendon rupture cases. The tendon injury cases were filed in both federal and state courts. Many were settled individually or in groups through confidential agreements. The tendon litigation predated the MDL and was largely resolved by the time the neuropathy cases were consolidated.

Aortic aneurysm cases. The aortic injury claims were filed in various state courts after the 2015 JAMA study and the 2018 FDA warning. These cases were never formally consolidated into a federal MDL. Some were dismissed or closed, but others remain active, particularly in jurisdictions with longer statutes of limitations or where the "discovery rule" (measuring the statute from when the patient learned of the drug connection) extends the filing window.

Levaquin discontinuation. In December 2017, Janssen Pharmaceuticals discontinued production of both the oral and intravenous formulations of Levaquin. While stopping short of a formal recall, the discontinuation came amid mounting litigation and the wide availability of alternative antibiotics. Generic levofloxacin remains available.

FQAD: the syndrome

The FDA's 2016 recognition of "fluoroquinolone-associated disability" (FQAD) is significant for both medical and legal purposes. FQAD describes a syndrome of multiple co-occurring effects involving tendons, muscles, joints, nerves, and the central nervous system that can occur together and can be disabling and potentially permanent.

The FQAD designation is important because individual symptoms (a sore Achilles, tingling in the feet, anxiety) might be dismissed as unrelated to the medication. The syndrome framework recognizes that these symptoms can be causally connected to the fluoroquinolone and can co-occur as a single drug-induced condition.

For patients who experienced multiple symptoms after taking a fluoroquinolone, the FQAD framework may strengthen a legal claim by connecting symptoms that might otherwise be attributed to multiple unrelated causes.

How fluoroquinolone cases compare to other mass torts

The fluoroquinolone litigation shares features with several Halstonberg-covered mass torts:

Depo-Provera meningioma (MDL 3140) similarly involves a widely prescribed drug with an evolving FDA warning timeline, where the delay between the scientific evidence and the label update is the central legal issue.

Elmiron pigmentary maculopathy similarly involves a delayed recognition of a drug-induced injury, where patients experienced symptoms for years before the connection to the medication was identified.

Ozempic and GLP-1 gastroparesis (MDL 3094) similarly involves a pharmaceutical product with a mechanism-related side effect (delayed gastric emptying) that the plaintiffs allege was inadequately warned.

The fluoroquinolone litigation is distinctive in several ways: the litigation has been ongoing for more than a decade (longer than most active mass torts), the FDA has issued an unusually large number of escalating warnings, a major defendant (Janssen) discontinued its product during the litigation, and the FQAD syndrome framework connects multiple injury categories that would otherwise be litigated separately.

The current landscape

The honest assessment for someone evaluating a potential fluoroquinolone claim in 2026:

The tendon and neuropathy litigation waves are largely concluded. Most claims in these categories have been settled or resolved. New tendon or neuropathy claims face statute-of-limitations challenges in many jurisdictions, because the injuries and the drug connection have been known for years (the 2008 and 2013 FDA warnings established widespread awareness).

The aortic aneurysm claims are still active. The 2018 FDA warning is more recent, and the discovery rule may extend the statute of limitations for patients who did not learn of the aortic connection until after the warning. Aortic aneurysm and dissection are severe, often life-threatening injuries with substantial damages.

FQAD-based claims are still developing. The 2016 FDA recognition of the syndrome is relatively recent, and patients who experience the full spectrum of FQAD symptoms may have claims with extended discovery-rule statutes.

The statute of limitations is the critical threshold. Each state has its own limitations period (typically 2-3 years from injury or discovery), and the "discovery rule" (when the patient first knew or should have known of the drug connection) determines the starting date. For many tendon and neuropathy patients, the discovery date has long passed; for aortic and FQAD patients, the discovery date may be more recent.

Practical guidance

For someone who took a fluoroquinolone and experienced a serious injury:

Identify which injury category applies. Tendon rupture, peripheral neuropathy, and aortic aneurysm/dissection are the three primary categories; FQAD (multiple co-occurring symptoms) is the overarching syndrome.

Evaluate the statute of limitations in your jurisdiction. The limitations period and the discovery rule are the threshold questions. If you became aware of the drug connection recently (particularly for aortic injuries or FQAD), the statute may still be open. For tendon injuries where you were aware of the connection years ago, the statute may have expired.

Gather medical records documenting the injury and the fluoroquinolone prescription. The prescription records (which drug, when, how long), the diagnostic records (tendon MRI, nerve conduction studies, aortic imaging), and the treatment records establish the claim.

For aortic aneurysm or dissection, the causal link to the fluoroquinolone is supported by the 2015 JAMA study and the 2018 FDA warning. The imaging confirming the aortic condition and the temporal relationship to the drug use are the key evidence.

Most lawyers who handled the peak of the fluoroquinolone litigation have closed their intake for new tendon and neuropathy cases. Counsel still taking new cases are generally focused on aortic injuries and FQAD claims. Confirm that any firm you contact is currently accepting fluoroquinolone cases and is candid about the statute-of-limitations analysis.

The fluoroquinolone litigation illustrates how drug safety information evolves over time. The injuries were real and serious, the FDA's response accumulated over a decade of escalating warnings, one manufacturer withdrew its product, and the litigation produced substantial (though confidential) settlements. For patients still experiencing the effects of fluoroquinolone injury, the aortic and FQAD pathways remain the most viable claims in the current landscape.